Gastroesophageal Junction Cancer News

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer

11/17/2023

Allison Casey

On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.

On November 16, 2023, the FDA...

11/17/2023

Oncology

News

Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer

08/10/2023

Allison Casey

In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.

In a phase 1b/2 study,...

08/10/2023

Oncology

News

Frontline Tislelizumab Plus Chemotherapy for Patients With Gastroesophageal Squamous Cell Carcinoma

05/23/2023

In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.

In a phase 3 trial, tislelizumab...

05/23/2023

Oncology

News

Zolbetuximab Plus CAPOX Improves Survival in Gastric/Gastroesophageal Junction Cancers

03/25/2023

Amber Denham

Zolbetuximab in combination with chemotherapy increases survival in patients with first-line claudin-18.2-positive/HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Zolbetuximab in combination with...

03/25/2023

Oncology

News

Potential of Sintilimab Plus Apatinib and Chemotherapy in Gastric or Gastroesophageal Junction Cancer

03/20/2023

Allison Casey

In a phase 2 study, sintilimab plus apatinib and chemotherapy demonstrated anti-tumor activity and tolerable safety among patients with gastric or gastroesophageal junction cancer.

In a phase 2 study, sintilimab...

03/20/2023

Oncology

News

Perioperative Nivolumab Plus Ipilimumab for dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

03/02/2023

Allison Casey

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab was associated with high pathological complete response with no unexpected toxicities for patient with dMMR/MSI-H gastric/gastroesophageal junction adenocarcinoma.

Neoadjuvant nivolumab plus...

03/02/2023

Oncology

News

Adding Atezolizumab to Modified FOLFOX May Improve Response Rates in Gastroesophageal Junction Cancer

02/10/2023

Allison Casey

The addition of atezolizumab to modified FOLFOX in the perioperative setting was found to be safe and may improve response rates for patients with gastroesophageal junction cancer.

The addition of atezolizumab to...

02/10/2023

Oncology

News

Potential of Overlap Guiding Tube-Assisted Method of Esophagojejunostomy for Gastric/Gastroesophageal Junction Cancer

02/08/2023

Allison Casey

Study findings reveal the overlap guided tube-assisted method of esophagojejunostomy for gastric/gastroesophageal junction cancer is associated with reduced surgical difficulty vs the conventional method.

Study findings reveal the...

02/08/2023

Oncology

News

Postoperative Adjuvant Chemotherapy Improves Survival Outcomes for Patients With Gastroesophageal Junction Adenocarcinoma

01/10/2023

According to a study, adjuvant chemotherapy after gastrectomy improved the overall survival and disease-free survival for patients with gastroesophageal junction adenocarcinoma, compared to gastrectomy alone.

According to a study, adjuvant...

01/10/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology